Keyvisual: View into a green forest

Our Portfolio

Direct Investments

We take an active role in our portfolio companies, contributing expertise in drug discovery, development and operations, to help them deliver maximum patient value.

Logo: StrideBio, Inc.

StrideBio, Inc. is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies.

  • 28 March 2019. StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases

    read more
  • 19 February 2019. CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

    read more
  • 03 January 2019. StrideBio Appoints Sapan Shah, Ph.D. as Chief Executive Officer

    read more

Logo: Rinri Therapeutics

Rinri Therapeutics is a biotechnology company developing advanced stem cell-based therapeutics to treat hearing loss.

  • 20 May 2019. Rinri Therapeutics secures £1.4 million seed funding to advance its novel regenerative cell therapy to treat sensorineural hearing loss

    read more

Logo: Locana, Inc.

Locana, Inc. is an RNA-targeting gene therapy company with a platform technology to address a wide spectrum of human genetic diseases.

  • 22 May 2019. Locana Raises $55 Million Series A Financing to Advance Portfolio of RNA-targeting Gene Therapies

    read more

Selected Invested Funds

Logo: Arix Bioscience plc

Arix Bioscience supports medical innovation at all stages of development and has access to breakthrough academic science.

Logo: Pappas Capital

Pappas is dedicated to furthering life science discoveries and delivering groundbreaking solutions to market.

Logo: Quiming Venture Partners

Qiming drives innovation and growth of business enterprises and promotes overall industry advancement and social development.